Cargando…

Metformin-induced preferential killing of breast cancer initiating CD44(+)CD24(−/low) cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts

Trastuzumab-refractory breast cancer stem cells (CSCs) could explain the high rate of primary resistance to single-agent trastuzumab in HER2 gene-amplified breast cancer patients. The identification of agents with strong selective toxicity for trastuzumab-resistant breast CSCs may have tremendous re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cufí, Sílvia, Corominas-Faja, Bruna, Vazquez-Martin, Alejandro, Oliveras-Ferraros, Cristina, Dorca, Joan, Bosch-Barrera, Joaquim, Martin-Castillo, Begoña, Menendez, Javier A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380574/ https://www.ncbi.nlm.nih.gov/pubmed/22565037

Ejemplares similares

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
por: Cufí, Sílvia, et al.
Publicado: (2013)

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
por: Cufí, Sílvia, et al.
Publicado: (2012)

Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2012)

Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: New insight into the role of mitophagy in cell stemness
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2012)

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2009)

Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs
por: Corominas-Faja, Bruna, et al.
Publicado: (2012)

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2013)

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
por: Cufí, Sílvia, et al.
Publicado: (2013)

Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties
por: Cuyàs, Elisabet, et al.
Publicado: (2015)

Metformin: Multi-faceted protection against cancer
por: Del Barco, Sonia, et al.
Publicado: (2011)

Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer
por: Menendez, Javier A., et al.
Publicado: (2011)

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
por: Oliveras-Ferraros, Cristina, et al.
Publicado: (2011)

Gerosuppressant Metformin: less is more
por: Menendez, Javier A., et al.
Publicado: (2011)

Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
por: Menendez, Javier A., et al.
Publicado: (2014)

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
por: Oliveras-Ferraros, C, et al.
Publicado: (2012)

CD56(bright) natural killer cells preferentially kill proliferating CD4(+) T cells
por: Lee, Mercede, et al.
Publicado: (2023)

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics
por: Puig-Costa, Manuel, et al.
Publicado: (2014)

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells
por: Corominas-Faja, Bruna, et al.
Publicado: (2014)

Trastuzumab‐based near‐infrared photoimmunotherapy in xenograft mouse of breast cancer
por: Yamashita, Susumu, et al.
Publicado: (2022)

Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
por: Cuyàs, Elisabet, et al.
Publicado: (2015)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer
por: Horlock, C, et al.
Publicado: (2009)

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
por: Cufí, Sílvia, et al.
Publicado: (2013)

A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
por: Puig, Teresa, et al.
Publicado: (2011)

CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells
por: Xiong, Lijuan, et al.
Publicado: (2016)

The nutritional phenome of EMT-induced cancer stem-like cells
por: Cuyàs, Elisabet, et al.
Publicado: (2014)

CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity
por: Wang, Yu, et al.
Publicado: (2017)

Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft
por: Pan, Anni, et al.
Publicado: (2018)

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
por: Martin-Castillo, Begoña, et al.
Publicado: (2018)

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
por: Palomeras, Sònia, et al.
Publicado: (2019)

CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
por: Song, Patrick N., et al.
Publicado: (2020)

Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo
por: Yang, Cuixia, et al.
Publicado: (2015)

Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells
por: Song, Chang W., et al.
Publicado: (2012)

Male Killing Spiroplasma Preferentially Disrupts Neural Development in the Drosophila melanogaster Embryo
por: Martin, Jennifer, et al.
Publicado: (2013)

Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2016)

Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
por: Rossini, Anna, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_93v32u9qo75rtgv8oheoo5nlav